Q current report, 19 December 2016

Business Context and Reporting Period

This Form 8-K reports on the 2016 Annual Meeting of Stockholders held by Akers Biosciences, Inc. on December 19, 2016. The filing details the results of shareholder votes regarding director elections, auditor ratification, and executive compensation.

Key Financial Metrics

The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance voting results.

Material Changes and Voting Results

A quorum was established with greater than 33.34% of outstanding shares present. The following matters were voted upon:

  • Director Elections: Raymond F. Akers, Jr., Ph.D, Thomas Knox, Brandon Knox, Robert E. Andrews, and Raza Bokhari were elected to one-year terms on the Board of Directors.
  • Auditor Ratification: The proposal to ratify Morison Cogen LLP as the independent registered public accountant for 2016 was adopted.
  • Executive Compensation: The non-binding advisory vote on executive compensation was approved.
Proposal Votes For Votes Against/Withheld Abstentions
Election of Raymond F. Akers, Jr., Ph.D 1,114,807 44 32,768
Election of Thomas Knox 1,035,180 308 112,113
Election of Brandon Knox 993,380 308 153,913
Election of Robert E. Andrews 1,035,295 308 111,998
Election of Raza Bokhari 1,007,980 308 139,313
Ratification of Morison Cogen LLP 1,928,133 349,744 2,000
Advisory Vote on Executive Compensation 1,043,284 76,041 27,792

Guidance, Outlook, and Risks

The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items.

Investor Verification Checklist

  • Verify the composition of the newly elected Board of Directors and their respective terms.
  • Confirm the appointment of Morison Cogen LLP as the independent auditor for the 2016 fiscal year.
  • Review the significant number of abstentions and votes against/withheld for specific director nominees (e.g., Brandon Knox and Raza Bokhari) to assess shareholder sentiment.
  • Check subsequent filings for the company's financial performance, as this 8-K contains no financial data.